现成Gore胸腹多分支内假体与医生改良内假体治疗复杂腹主动脉及胸腹主动脉瘤的三年结局
单中心回顾性比较2020至2022年接受TAMBE(12例)或PMEG(56例)的复杂主动脉瘤患者,TAMBE组上肢入路比例更高、手术时间更长,两组技术成功率、30天死亡率及3年免于再干预率无显著差异,再干预均较常见。
要点
- TAMBE组上肢入路100% vs PMEG组63%,手术时间247±36分钟 vs 189±49分钟(P<.001)。
- 两组技术成功率100% vs 95%(P=.412),30天死亡率均为0。
- 3年免于再干预率56% vs 62%(log-rank P=.910),再干预率33% vs 27%(P=.646)。
核心结论
- 在有经验的中心,FB-EVAR可分别用PMEG或TAMBE完成,围手术期和中期结局相当且优良。
- TAMBE和PMEG均常需再干预。
研究设计与样本
- 单中心回顾性研究,纳入2020至2022年作为多中心关键试验一部分接受TAMBE或作为前瞻性医生发起研究性器械豁免一部分接受PMEG的患者。
- 共68例,TAMBE组12例,PMEG组56例。
主要发现
- TAMBE组上肢入路比例高于PMEG组(100% vs 63%,P=.013),平均手术时间更长(247±36分钟 vs 189±49分钟,P<.001)。
- 技术成功率TAMBE组100% vs PMEG组95%(P=.412),两组30天死亡率均为0。
- TAMBE组无重大不良事件;PMEG组呼吸衰竭2%、需透析2%、脊髓缺血4%。
- 总体内漏率TAMBE组50% vs PMEG组41%(P=.57),TAMBE组内漏均为II型,PMEG组11%出现I型或III型内漏。
- 中位随访TAMBE组26.7个月、PMEG组21.2个月,靶血管不稳定率10.4% vs 6.9%(P=.401);再干预率33% vs 27%(P=.646);3年免于再干预率56% vs 62%(log-rank P=.910);3年免于内脏肾靶血管不稳定率两组均为89%(log-rank P=.459);Kaplan-Meier 3年估计生存率TAMBE组100% vs PMEG组77%(log-rank P=.157)。
临床怎么用
- 在有经验的中心,TAMBE和PMEG均可用于FB-EVAR,围手术期和中期结局相当且优良。
- TAMBE和PMEG术后均常需再干预。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Fenestrated-branched endovascular aortic repair (FB-EVAR) has shown favorable outcomes for repair of complex aneurysms and thoracoabdominal aortic aneurysms. Physician-modified endografting (PMEG) and the Gore thoracoabdominal multibranch endoprosthesis (TAMBE) provide custom and off-the-shelf devices for FB-EVAR, respectively. This study compares the outcomes of TAMBE and PMEG at a single institution. METHODS: A retrospective review of patients who underwent TAMBE as part of the multicenter pivotal trial or PMEG as part of a prospective physician-sponsored investigational device exemption at a single institution between 2020 and 2022 were completed. Patient demographics, characteristics, and perioperative and midterm outcomes were compared. RESULTS: A total of 68 patients were included, with 12 in the TAMBE group and 56 in the PMEG group. Baseline characteristics were comparable between groups. Aneurysm type was most often thoracoabdominal aortic aneurysm in both groups (58% TAMBE and 52% PMEG). TAMBE had a higher rate of upper extremity access (100% vs 63%; P = .013) and longer mean procedure time (247 ± 36 minutes vs 189 ± 49 minutes; P < .001). Other intraoperative metrics were similar between groups. Technical success was 100% in TAMBE and 95% in PMEG (P = .412). There was no 30-day mortality in either group. No major adverse events occurred with TAMBE, whereas in PMEG cases, 2% had respiratory failure, 2% required dialysis, and 4% experienced spinal cord ischemia. Although the overall endoleak rates were similar (50% of TAMBE vs 41% of PMEG; P = .57), type II endoleaks accounted for all of the endoleaks in the TAMBE group, whereas type I or III endoleaks were seen in 11% of PMEG patients. At a median follow-up of 26.7 months for the TAMBE group and 21.2 months for the PMEG group, target vessel instability was seen in 10.4% of TAMBE, and 6.9% of PMEG targeted branches (P = .401). Reintervention was required in 33% of TAMBE patients and 27% of PMEG patients (P = .646). Estimated freedom from reintervention rates at 3 years were similar (56% TAMBE vs 62% PMEG, log-rank P = .910). Freedom from visceral renal target vessel instability at 3 years was 89% for both groups (log-rank P = .459). The Kaplan-Meier 3-year estimated survival was 100% for patients in the TAMBE group and 77% for patients in the PMEG group (log-rank P = .157). CONCLUSIONS: At experienced centers, FB-EVAR can be completed with PMEG or TAMBE with comparable, excellent perioperative and midterm outcomes. Reinterventions are frequently needed for both TAMBE and PMEG.
引用
- DiBartolomeo AD, Manesh M, Hong J, et al. Three-year outcomes of off-the-shelf Gore thoracoabdominal multibranch endoprosthesis and physician-modified endografts for complex abdominal and thoracoabdominal aortic aneurysms. J Vasc Surg. 2024. PMID: 39181341. doi:10.1016/j.jvs.2024.07.107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。